- Company
- Y-Biologics has transferred anti-cancer drug technology
- by An, Kyung-Jin Jul 8, 2021 05:58am
- Y-Biologics announced on the 6th that it has signed a license agreement with French pharmaceutical group Pierre Fabre for antibody candidates. The deal is worth up to 116.4 billion won, including upfront fee and Milestone. Under the deal, Y-Biologics grants Pierre Fabre the right to exclusively develop and commercialize YBL-003, which has
- Company
- MFDS in a month-long silence regarding Champix issue
- by Jul 7, 2021 05:54am
- Confusion in the field continues as the impurity issue of the smoking cessation treatment ‘Champix(varenicline)’ remains unresolved. Contrary to the U.S. and Canada, where the authorities preemptively provided guidelines to patients and HCPs while notifying them of the product recall and the possibility of impurities, the Korean health aut
- Company
- [Reporter's view] Korean patients to name specific drugs
- by Eo, Yun-Ho Jul 7, 2021 05:54am
- A growing number of patients are looking for specific "Rx drugs." Patients who wanted certain OTC by visiting pharmacies are now finding a doctor and wanting certain Rx drugs. It is said that the demand for prescription, which was made in the past in the line of original and generics, is even spreading to the area of anticancer drugs. T
- Policy
- Generic prices are 41-54% more expensive than foreign ones
- by Lee, Hye-Kyung Jul 7, 2021 05:53am
- The level of generic prices in Korea is 41 to 54% higher than that of foreign generics. This leads to an interpretation that if domestic generics are replaced with foreign medicines, 41-54% of costs will be reduced if only tariffs and transportation costs are compared. The findings were recently published by The Korean Association of Heal
- Product
- Consult with MD about controversy over Champix?
- by Jul 7, 2021 05:53am
- Concerns over the detection of carcinogens in the anti-smoking supplementary drug Champix (Varenicline), pharmacies are also making a series of inquiries. However, there are no clear guidelines for existing patients, adding to the confusion. As part of preemptive measures related to the impurity crisis, the domestic supply has been complet
- Policy
- ‘Immunoglobulin inj’ is reimbursed for vaccine-related TTS
- by Lee, Hye-Kyung Jul 7, 2021 05:52am
- Human Immunoglobulin G may now be used with insurance benefits for the treatment of thrombosis thrombocytopenia syndrome (TTS), a known adverse event following COVID-19 vaccinations. Expansion of benefit standards for general drugs usually takes around 80 days, however, due to the specificity of the COVID-19 situation, the reimbursement stan
- Company
- The NPS bought shares in Samsung BioLogics & SK Bio
- by Kim, Jin-Gu Jul 6, 2021 05:51am
- The National Pension Service (NPS), the nation's largest institutional investor, significantly reduced its investment in the local stock market in the first half of last year. Investment in pharmaceutical bio stocks has rather increased. Investments in Samsung BioLogics, SK Bioscience, and SK Biopharm were significant. It sold more than &836
- Policy
- Benefit extended for Lipiodol, reduced for Imotun from 23rd
- by Kim, Jung-Ju Jul 6, 2021 05:50am
- Reimbursement benefit for Guerbet Korea’s liver cancer contrast medium Lipiodol Ultra-Fluid (iodised oil, 12.8g/10mL) will be extended to lymphangiography and sialography. On the other hand, reimbursement benefit for Chong Kun Dang Pharmaceutical’s avocado and soyabeam unsaponifiables, Imotun Cap., will be reduced in line with its reduced indi
- Policy
- Cholib was eventually withdrawn from the domestic market
- by Lee, Tak-Sun Jul 6, 2021 05:50am
- Abbott's Cholib, the first combination of Fenofibrate-Simvastatin released in Korea, will be withdrawn from the Korean market. This is because the Statin-Fenofibrate market was lagging behind domestic pharmaceutical companies and administrative disposition by the MFDS was underway. According to industries on the 2nd, South Korea's Abbott info
- Policy
- Domestic companies attempt at hemophilia treatment market
- by Moon, sung-ho Jul 6, 2021 05:50am
- Domestic pharmaceutical companies have thrown their hats into the domestic hemophilia treatment market, forewarning a change in the prescription market. The attempts will mainly target the large major hospitals that treat hemophilia, but the possibility of any significant change in the treatment market is considered low in the field. Ac
